Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel
| dc.contributor.author | Heidenreich, Axel | |
| dc.contributor.author | Matus, Geoffrey | |
| dc.contributor.author | Hitier, Simon | |
| dc.contributor.author | Bahl, Amit | |
| dc.contributor.author | Basaran, Mert | |
| dc.contributor.author | Malik, Zafar I. | |
| dc.contributor.author | Di Lorenzo, Giuseppe | |
| dc.contributor.author | Ardavanis, Alexandros | |
| dc.contributor.author | Parente, Phillip | |
| dc.contributor.author | de Schultz, Wito | |
| dc.contributor.author | Saad, Fred | |
| dc.contributor.author | van Oort, Inge | |
| dc.contributor.author | Gerritsen, Winald R. | |
| dc.contributor.author | Aparicio, Luis M. Anton | |
| dc.date.accessioned | 2021-03-04T07:56:47Z | |
| dc.date.available | 2021-03-04T07:56:47Z | |
| dc.identifier.citation | Malik Z. I. , Di Lorenzo G., Basaran M., Ardavanis A., Parente P., de Schultz W., Saad F., van Oort I., Gerritsen W. R. , Aparicio L. M. A. , et al., "Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel", 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_60b4859d-5f25-4082-a679-7bdfb7378960 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/67461 | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.title | Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel | |
| dc.type | Bildiri | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 31 | |
| dc.contributor.firstauthorID | 141625 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Bildiri [64839]